CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients

Pharmacogenomics

Volumn 14, Issue 9, 2013, Pages 1027-1036

  Gijsen, Violette Mgj ^a,b   Van Schaik, Ron Hn ^c   Elens, Laure ^c,d   Soldin, Offie P ^e   Soldin, Steven J ^e   Koren, Gideon ^b,f   De Wildt, Saskia N ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Children; CYP3A4*22; Heart transplantation; Pharmacogenetics; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY; CYP3A4 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CARDIAC GRAFT REJECTION; CHILD; CYP3A GENE; CYP3A4 GENE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRESCHOOL CHILD; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; ALLELE; DONOR; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETICS; RETROSPECTIVE STUDY;

ALLELES; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION; GENOTYPE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; TACROLIMUS; TISSUE DONORS;

EID: 84880461075     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.80     Document Type: Article

References (26)

1. Penninga L, Møller CH, Gustafsson F, Steinbrüchel DA, Gluud C. Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: Systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur. J. Clin. Pharmacol. 66(12), 1177-1187 (2010).
2. Robinson BV, Boyle GJ, Miller SA et al. Optimal dosing of intravenous tacrolimus following pediatric heart transplantation. J. Heart Lung Transplant. 18(8), 786-791 (1999).
3. Aidong W, Zhenjie C, Tong L et al. Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation. Transplant. Proc. 36(8), 2388-2389 (2004).
4. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin. Pharmacokinet. 49(3), 141-175 (2010).
5. Kniepeiss D, Renner W, Trummer O et al. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. Clin. Transplant. 25(1), 146-150 (2011).
6. Zheng H, Webber S, Zeevi A et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant. 3(4), 477-483 (2003).
7. Gijsen V, Mital S, van Schaik RH et al. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J. Heart Lung Transplant. 30(12), 1352-1359 (2011).
8. Danielson PB. The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans. Curr. Drug Metab. 3(6), 561-597 (2002).
9. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54(10), 1271-1294 (2002).
10. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270(1), 414-423 (1994).
11. Westlind A, Löfberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem. Biophys. Res. Commun. 259(1), 201-205 (1999).
12. Westlind-Johnsson A, Malmebo S, Johansson A et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab. Dispos. 31(6), 755-761 (2003).
13. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11(4), 274-286 (2011).
14. Elens L, van Schaik RH, Panin N et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood concentrations in stable renal transplant patients. Pharmacogenomics 12(10), 1383-1396 (2011).
15. Elens L, Bouamar R, Hesselink DA et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 57(11), 1574-1583 (2011).
16. Stewart S, Winters GL, Fishbein MC et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J. Heart Lung Transplant. 24(11), 1710-1720 (2005).
17. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr. Clin. North Am. 34(3), 571-590 (1987).
18. Volosov A, Napoli KL, Soldin SJ Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography-tandem mass-spectrometry chromatography-tandem mass-spectrometry. Clin. Biochem. 34(4), 285-290 (2001).
19. van Schaik RHN, Van Der Heiden IP, Van Den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin. Chem. 48(10), 1668-1671 (2002).
20. Hesselink DA, van Schaik RHN, Van Der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74(3), 245-254 (2003).
21. Rodriguez S, Gaunt TR, Day INM. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am. J. Epidemiol. 169(4), 505-514 (2009).
22. Leeder JS. Developmental and pediatric pharmacogenomics. Pharmacogenomics 4(3), 331-341 (2003).
23. Blake MJ, Castro L, Leeder JS, Kearns GL. Ontogeny of drug metabolizing enzymes in the neonate. Semin. Fetal Neonatal Med. 10(2), 123-138 (2005).
24. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349(12), 1157-1167 (2003).
25. Malluche H, Sawaya BP, Hakim RM, Sayegh MH. Clinical Nephrology, Dialysis and Transplantation. Dustri-Verlag, FL, USA (2004).
26. Urbschat A, Obermüller N, Haferkamp A. Biomarkers of kidney injury. Biomarkers. 16(Suppl. 1), S22-30 (2011). Wildt)